TargetBeta
CEACAM5
CEA cell adhesion molecule 5 · also CD66e, CEA · CD molecules
6 programs in company-led studies act on CEACAM5, from 6 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| precemtabart tocentecanrule | Merck KGaA, Darmstadt, Germany | phase 3 | 43 running | – | NCIt |
| Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 | Sino Biopharmaceutical | phase 2 | 22 running | TNFRSF9 | the company's pipeline |
| Anti-CEACAM5 Antibody-drug Conjugate BMS-986490rule | Bristol-Myers Squibb | phase 2 | 11 running | – | NCIt |
| Anti-CEACAM5 Antibody-drug Conjugate IBI3020rule | Innovent Biologics | phase 1 | 11 running | – | NCIt |
| RO7821657rule | Hoffmann-La Roche | phase 1 | 11 running | – | the studies' text |
| tusamitamab sonditecan | Pfizer | phase 1 | 11 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Colorectal Neoplasms, 3 programs
- Stomach Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 23, 2027precemtabart tocentecan · Merck KGaA, Darmstadt, Germany · phase 3 · NCT06710132
- Dec 31, 2027Anti-CEACAM5 Antibody-drug Conjugate IBI3020 · Innovent Biologics · phase 1 · NCT06963281
- May 21, 2028Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 · Sino Biopharmaceutical · phase 2 · NCT07387081
- Sep 12, 2029tusamitamab sonditecan · Pfizer · phase 1 · NCT06131840
- May 31, 2030RO7821657 · Hoffmann-La Roche · phase 1 · NCT07883577
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.